The FDA's Pharmacy Compounding Advisory Committee (PCAC) has voted on seven high-volume research peptides. Over two days — July 23-24, 2026, at the FDA's White Oak campus — the committee weighed whether BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon belong on the list that lets compounding pharmacies legally prepare them.
The final count: six of the seven were recommended for the 503A bulks list, and one was rejected. On Day 1, the committee handed a clean sweep to the four peptides it considered — BPC-157, TB-500, KPV, and MOTS-c — each cleared by a narrow margin. On Day 2, Semax (8-5) and Epitalon (7-4) were added to the recommendation, while DSIP — also called emideltide — was the lone rejection, failing 6-7 with one abstention. Every recommendation came over the objection of the FDA's own scientists, whose briefing documents had advised adding none of the seven.
Research-context information only. BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon are research peptides sold for research purposes only. Regulatory details and timelines below come from public FDA records and the meeting proceedings. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
The verdict, peptide by peptide
The committee voted on each compound for inclusion on the 503A Bulk Drug Substances List — the list that permits a compounding pharmacy to prepare a substance against an individual prescription. Day 1 (July 23) covered BPC-157, TB-500, KPV, and MOTS-c; Day 2 (July 24) covered DSIP (also called emideltide), Semax, and Epitalon. The docket is FDA-2025-N-6895.
| Peptide | Day | Recommendation | Vote |
|---|---|---|---|
| BPC-157 | July 23 | Recommended | 8-6 (1 abstained) |
| TB-500 | July 23 | Recommended | 8-6 (1 abstained) |
| KPV | July 23 | Recommended | 8-6 (1 abstained) |
| MOTS-c | July 23 | Recommended | 7-5 (2 abstained) |
| DSIP (emideltide) | July 24 | Not recommended | 6-7 (1 abstained) |
| Semax | July 24 | Recommended | 8-5 |
| Epitalon | July 24 | Recommended | 7-4 |
The surprising part is the source of the opposition. The FDA's own briefing documents had proposed the same conclusion for every one of the seven peptides — do not add them to the 503A list — citing thin clinical evidence and questions about manufacturing consistency. The committee voted the other way on six of them. According to FDA briefing materials, the docket entries described proposed compounding uses — BPC-157's cited ulcerative colitis, KPV's cited wound healing and inflammatory conditions, and MOTS-c's cited obesity and osteoporosis — the same nominations FDA staff had reviewed and recommended against.
DSIP was the exception. The committee rejected it 6-7 with one abstention, the only peptide of the seven to fail. According to contemporaneous reporting, members flagged especially weak evidence: the compound was nominated as a subcutaneous injection for indications including narcolepsy and opioid withdrawal, yet the cited human studies used an intravenous route and amounted to a single narcolepsy case report and two small, uncontrolled opioid-withdrawal studies.
The narrow splits — 8-6 on three of the Day-1 four, 7-5 on MOTS-c, 8-5 for Semax, 7-4 for Epitalon, with abstentions on several — reflect how divided the room was. Members who voted yes pointed to patient and physician demand and to compounding pharmacies' existing preparation practices; dissenters echoed the staff's evidence concerns. The committee's recommendation is advisory, and several members noted on the record that a yes vote is a signal to the FDA, not a rule change.
What the result means for access
The most important framing the headlines miss: all seven already came off the FDA's Category 2 "may not be compounded" list on April 23, 2026. So this vote was never a re-ban risk — it was an upside decision. Here is what each outcome direction means:
- Recommended for the 503A list: a legal compounding pathway can eventually open — but not immediately. The recommendation is advisory; the FDA still has to review it and initiate its own rulemaking, a process that typically runs through 2027. Nothing about sourcing changes the day of the vote.
- Voted against: no new legal compounding channel opens. Research-use-only sourcing remains the only route while the broader regulatory picture plays out. It does not re-impose the Category 2 restriction that was lifted in April.
- Deferred / no consensus: the question carries to a future meeting; the status quo holds in the meantime.
In every case, the practical near-term reality for buyers is the same: the research-use-only market is unchanged by the meeting itself.
